Advice
Following a full submission.
Rotigotine (Neupro) is not recommended for use within NHS Scotland for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease as monotherapy (i.e. without levodopa).
Rotigotine was superior to placebo in two randomised controlled trials. However, in one active comparator study non-inferiority to another non-ergolinic dopamine agonist comparator was not shown. The economic case has not been demonstrated.
Download detailed advice46KB (PDF)
Medicine details
- Medicine name:
- rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro)
- SMC ID:
- 289/06
- Indication:
- Early-stage idiopathic Parkinson' s disease as monotherapy
- Pharmaceutical company
- Schwarz Pharma Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 07 August 2006